The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.
 
Daniel Lee
No Relationships to Disclose
 
Alexander Yang
No Relationships to Disclose
 
Madeline McNamara
No Relationships to Disclose
 
Harriet M. Kluger
Consulting or Advisory Role - Bristol-Myers Squibb; ChemoCentryx; Clinigen Group; Eisai; GI Reviewers; Gigagen; Invox; Iovance Biotherapeutics; Merck; Pliant; Seranova Bio; Signatera; Werewolf Pharma
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Thuy Tran
No Relationships to Disclose
 
Kelly Olino
Patents, Royalties, Other Intellectual Property - Patent pending for the use of mRNA vaccine for the treatment of virally associated cancers.
 
James Clune
No Relationships to Disclose
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Asher Biotherapeutics; EvolveImmune Therapeutics; GlaxoSmithKline; Intensity Therapeutics; Johnson & Johnson/Janssen; Nextcure; Normunity; Oncohost; Repertoire Immune Medicines; Rootpath
Consulting or Advisory Role - Adagene; Adaptimmune; Agenus; Alligator Bioscience; AnaptysBio; AstraZeneca/MedImmune; Biond Biologics; BioNTech; Bristol-Myers Squibb; Dragonfly Therapeutics; Genocea Biosciences; Gilead Sciences; immunocore; Innate Pharma; Iovance Biotherapeutics; ITeos Therapeutics; Jazz Pharmaceuticals; Kadmon; Kanaph Therapeutics; Merck; Molecular Partners; Numab; Ocellaris Pharma; OncoSec; Pfizer; Pierre Fabre; PIOtx; Pliant; Regeneron; Sapience Therapeutics; Seagen; Simcha Therapeutics; Simcha Therapeutics; ST Cube; Targovax; Tessa Therapeutics; Turnstone Bio; Verastem; Xilio Therapeutics
Other Relationship - CEC Oncology; Physicans' Education Resource
 
Jeffrey Joseph Ishizuka
Stock and Other Ownership Interests - Jounce Therapeutics; Kronos Bio
Consulting or Advisory Role - Danger Bio; Phenomic AI; Rheos Medicines; Tango Therapeutics
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - I am an inventor on a patent on approaches targeting dsRNA sensing titled: "MODULATING dsRNA EDITING, SENSING, AND METABOLISM TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY AND/OR MODULATORS OF INTRATUMORAL INTERFERON".